2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-171001
    ZM522 1454575-38-2
    ZM522 is a CD73 inhibitor with an IC50 value of 0.56 μM. ZM522 effectively increases the levels of interferon-γ (INF-γ) and enhances immune activity by regulating the activation status of T cells. ZM522 holds promise for research in the fields of immunology and cancer therapy.
    ZM522
  • HY-171237
    mPGES1-IN-9 556033-92-2
    mPGES1-IN-9 (compound 1_8) is a mPGES1 inhibitor (IC50=0.5 μM), which can be used in anti-inflammatory research.
    mPGES1-IN-9
  • HY-171279
    Casein kinase 1δ-IN-29 1177418-39-1
    Casein kinase 1δ-IN-29 (Compound 18) is the inhibitor for p38α and casein kinase 1 that inhibits p38α, CK1δ and CK1ε with IC50 of 0.041 µM, 0.005 µM and 0.447 µM, respectively. Casein kinase 1δ-IN-29 arrests cell cycle at subG1 phase, induces apoptosis in cell AC1-M88.
    Casein kinase 1δ-IN-29
  • HY-171290
    Casein kinase 1δ-IN-31 2567490-30-4
    Casein kinase 1δ-IN-31 (Compound 16) is the inhibitor for casein kinase (CK) that inhibits CK1α, CK1δ, and p38α with IC50s of 196, 17, and 18 nM, respectively. Casein kinase 1δ-IN-31 inhibits Double Homeobox 4 (DUX4) with IC50 of 1200 nM.
    Casein kinase 1δ-IN-31
  • HY-171297
    p38-α MAPK-IN-10 200801-77-0
    p38-α MAPK-IN-10 (Compound 6) is the inhibitor for p38α with an IC50 of 4 nM.
    p38-α MAPK-IN-10
  • HY-171300
    p38α inhibitor 8 1572047-63-2
    p38α inhibitor 8 (Compound 1) exhibits inhibitory activity against p38α MAPK and CK1δ with IC50 of 0.21 µM and 0.202 µM[1]>.
    p38α inhibitor 8
  • HY-171301
    p38α MAPK/CK1δ inhibitor-1 1572047-84-7
    p38α MAPK/CK1δ inhibitor-1 (Compound 3) exhibits inhibitory activity against p38α MAPK and CK1δ with IC50s of 0.185 µM and 0.089 µM.
    p38α MAPK/CK1δ inhibitor-1
  • HY-171467
    MRS7799 224040-19-1
    MRS7799 is a selective A 3 Adenosine Receptor antagonist agsinst human, mouse, and rat A3AR with Kds of 0.55, 3.74 and 2.80 nM, respectively. MRS7799 can be used in the study of neurodegeneration, cancer, ischemia of the heart and brain, autoimmune inflammatory diseases.
    MRS7799
  • HY-171589
    NLRP3-IN-77 2924547-57-7
    NLRP3-IN-77 (Compound 7n) is a potent NLRP3 inflammasome inhibitor. NLRP3-IN-77 inhibits the viability of THP-1 cells with an IC50 value of 5.36 nM. NLRP3-IN-77 can effectively reduce the secretion of interleukin-1β (IL-1β) and interleukin-18 (IL-18). NLRP3-IN-77 is promising for research of diseases related to the abnormal activation of the NLRP3 inflammasome, such as cancer and inflammatory diseases.
    NLRP3-IN-77
  • HY-171590
    SIK2-IN-3 2810809-10-8
    SIK2-IN-3 is an orally active SIK1/2 selective inhibitor (IC50: 0.128/0.084 μM). SIK2-IN-3 inhibits CRTC3 phosphorylation and myeloid cell pro-inflammatory cytokine production. SIK2-IN-3 ameliorates systemic and tissue inflammatory responses in a mouse anti-CD40 colitis model.
    SIK2-IN-3
  • HY-171592
    RIPK2-IN-7 2789711-40-4
    RIPK2-IN-7 (Compound 10w) is an orally active, selective RIPK2 inhibitor (IC50: 0.6 nM). RIPK2-IN-7 inhibits RIPK2 kinase activity, blocks the nucleotide-binding oligomerization domain (NOD) signaling pathway, and reduces the production of inflammatory factors (such as TNFα). RIPK2-IN-7 can be used in the study of inflammatory bowel disease (IBD).
    RIPK2-IN-7
  • HY-171658
    R1-ICR-5 3070346-91-4
    R1-ICR-5 is a selective PROTAC degrader that targets serine/threonine-protein kinase 1 (RIPK1). R1-ICR-5 mediates the degradation of RIPK1 through VHL, thereby deregulating the TNFR1 and TLR3/4 signaling hubs, enhancing the output of NF-κB, MAPK, and IFN signaling, and simultaneously promoting the activation of RIPK3 and the induction of necroptosis. R1-ICR-5 is promising for research of cancers and inflammatory diseases. (Pink: PK68 (HY-128348); Black: linker (HY-W012241); Blue: (S,R,S)-AHPC (HY-125845).
    R1-ICR-5
  • HY-172087
    VDR agonist 3
    VDR agonist 3 (Compound E15) is a potent vitamin D receptor (VDR) agonist. VDR agonist 3 can effectively inhibit HSC activation through VDR. VDR agonist 3 significantly reduces liver fibrosis without causing hypercalcemia in a CCl4-induced mouse liver fibrosis model.
    VDR agonist 3
  • HY-172090
    MASP-2-IN-1
    MASP-2-IN-1 (Compound 77) is the inhibitor for mannan-binding lectin-associated serine protease (MASP), that inhibits MASP2 and MASP3 with IC50 of 11.4 nM and 13.2 µM. MASP-2-IN-1 exhibits a weak inhibitory activity against hERG with an IC50 of 175 µM. MASP-2-IN-1 reveals a poor stability in mouse plasma with a half-life of 4.4 hours.
    MASP-2-IN-1
  • HY-172099
    EP4 receptor agonist 3 634193-29-6
    EP4 receptor agonist 3 is an EP4 receptor agonist that can be used in the study of colitis models in mice with DSS.
    EP4 receptor agonist 3
  • HY-172102
    NLRP3-IN-68
    NLRP3-IN-68 (Compound 2d) is a 1,3,4-oxadiazole derivative. NLRP3-IN-68 has strong anti-inflammatory and antioxidant activities, which can inhibit inflammatory cytokines secretion, iNOS expression and NLRP3 inflammasome activation. NLRP3-IN-68 can be used in the research of anti-inflammatory drugs.
    NLRP3-IN-68
  • HY-172105
    Anti-NASH agent 2 3028778-28-8
    Anti-NASH agent 2 (compound 21) is an inhibitor of de novo adipogenesis activity and α-SMA gene expression. Anti-NASH agent 2 improves hepatic steatosis, edema, inflammatory infiltrates, and liver fibrosis in NASH mouse models.
    Anti-NASH agent 2
  • HY-172107
    HPK1-IN-56 2901054-39-3
    HPK1-IN-56 (Compound A29) is a HPK1 inhibitor (IC50: 2.70 nM). HPK1-IN-56 inhibits downstream p-SLP76 (IC50: 8.1 nM in Jurkat T cells). HPK1-IN-56 induces the production of IL-2 in human PBMCs. HPK1-IN-56 has anticancer effect, enhances T-cell killing ability and the antitumor efficacy of anti-PD-1 antibody.
    HPK1-IN-56
  • HY-172133
    HDAC3-IN-6
    HDAC3-IN-6 (Compound SC26) is a selective HDAC3 inhibitor with an IC50 of 53 nM. HDAC3-IN-6 dose-dependently induces the expression of PD-L1. HDAC3-IN-6 induces more pronounced Apoptosis and production of ROS. HDAC3-IN-6 exhibits high antitumor efficacy against colorectal cancer.
    HDAC3-IN-6
  • HY-172134
    NLRP3-IN-70 1997362-01-2
    NLRP3-IN-70 (Compound 5m) is an NLRP3 inflammasome inhibitor with low oral bioavailability. NLRP3-IN-70 can directly bind to the NACHT domain of the NLRP3 protein and block the interaction of NLRP3 and ASC, thus inhibiting ASC oligomerization and NLRP3 inflammasome assembly. NLRP3-IN-70 can be used in the research of sepsis and nonalcoholic steatohepatitis.
    NLRP3-IN-70
Cat. No. Product Name / Synonyms Application Reactivity